153 related articles for article (PubMed ID: 21864640)
1. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.
Hašková P; Koubková L; Vávrová A; Macková E; Hrušková K; Kovaříková P; Vávrová K; Simůnek T
Toxicology; 2011 Nov; 289(2-3):122-31. PubMed ID: 21864640
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury.
Hašková P; Jansová H; Bureš J; Macháček M; Jirkovská A; Franz KJ; Kovaříková P; Šimůnek T
Toxicology; 2016 Sep; 371():17-28. PubMed ID: 27744045
[TBL] [Abstract][Full Text] [Related]
3. Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity.
Hašková P; Kovaříková P; Koubková L; Vávrová A; Macková E; Simůnek T
Free Radic Biol Med; 2011 Feb; 50(4):537-49. PubMed ID: 21147217
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.
Bendova P; Mackova E; Haskova P; Vavrova A; Jirkovsky E; Sterba M; Popelova O; Kalinowski DS; Kovarikova P; Vavrova K; Richardson DR; Simunek T
Chem Res Toxicol; 2010 Jun; 23(6):1105-14. PubMed ID: 20521781
[TBL] [Abstract][Full Text] [Related]
5. The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity.
Mladĕnka P; Kalinowski DS; Haskova P; Bobrovová Z; Hrdina R; Simůnek T; Nachtigal P; Semecký V; Vávrová J; Holeckova M; Palicka V; Mazurová Y; Jansson PJ; Richardson DR
Chem Res Toxicol; 2009 Jan; 22(1):208-17. PubMed ID: 19172757
[TBL] [Abstract][Full Text] [Related]
6. Iron chelators can protect against oxidative stress through ferryl heme reduction.
Reeder BJ; Hider RC; Wilson MT
Free Radic Biol Med; 2008 Feb; 44(3):264-73. PubMed ID: 18215735
[TBL] [Abstract][Full Text] [Related]
7. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
8. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
Hasinoff BB; Schroeder PE; Patel D
Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
[TBL] [Abstract][Full Text] [Related]
9. Direct administration of rutin does not protect against catecholamine cardiotoxicity.
Mladenka P; Zatloukalová L; Simůnek T; Bobrovová Z; Semecký V; Nachtigal P; Hasková P; Macková E; Vávrová J; Holecková M; Palicka V; Hrdina R
Toxicology; 2009 Jan; 255(1-2):25-32. PubMed ID: 18992299
[TBL] [Abstract][Full Text] [Related]
10. SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death.
Simůnek T; Boer C; Bouwman RA; Vlasblom R; Versteilen AM; Sterba M; Gersl V; Hrdina R; Ponka P; de Lange JJ; Paulus WJ; Musters RJ
J Mol Cell Cardiol; 2005 Aug; 39(2):345-54. PubMed ID: 15978614
[TBL] [Abstract][Full Text] [Related]
11. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
Hasinoff BB; Patel D
J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A
J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460
[TBL] [Abstract][Full Text] [Related]
13. Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.
Jansová H; Macháček M; Wang Q; Hašková P; Jirkovská A; Potůčková E; Kielar F; Franz KJ; Simůnek T
Free Radic Biol Med; 2014 Sep; 74():210-21. PubMed ID: 24992833
[TBL] [Abstract][Full Text] [Related]
14. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
15. Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine.
Hašková P; Applová L; Jansová H; Homola P; Franz KJ; Vávrová K; Roh J; Šimůnek T
Sci Rep; 2022 Jun; 12(1):9765. PubMed ID: 35697900
[TBL] [Abstract][Full Text] [Related]
16. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
17. Alternative treatment paradigm for thalassemia using iron chelators.
Szuber N; Buss JL; Soe-Lin S; Felfly H; Trudel M; Ponka P
Exp Hematol; 2008 Jul; 36(7):773-85. PubMed ID: 18456387
[TBL] [Abstract][Full Text] [Related]
18. Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury.
Říha M; Hašková P; Martin J; Filipský T; Váňová K; Vávrová J; Holečková M; Homola P; Vítek L; Palicka V; Šimůnek T; Mladěnka P
Oxid Med Cell Longev; 2016; 2016():5213532. PubMed ID: 26788248
[TBL] [Abstract][Full Text] [Related]
19. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).
Sterba M; Popelová O; Simůnek T; Mazurová Y; Potácová A; Adamcová M; Guncová I; Kaiserová H; Palicka V; Ponka P; Gersl V
Toxicology; 2007 Jun; 235(3):150-66. PubMed ID: 17459556
[TBL] [Abstract][Full Text] [Related]
20. Intralysosomal iron chelation protects against oxidative stress-induced cellular damage.
Kurz T; Gustafsson B; Brunk UT
FEBS J; 2006 Jul; 273(13):3106-17. PubMed ID: 16762036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
